Trials / Withdrawn
WithdrawnNCT02100618
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
Evaluation of Antibody Persistence for GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 15 Years – 32 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to establish the long-term persistence of the immune response and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary study (NCT00541970).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling | Blood samples will be collected from all subjects at Year 6.5 |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-04-01
- Last updated
- 2015-07-20
Source: ClinicalTrials.gov record NCT02100618. Inclusion in this directory is not an endorsement.